Since the mid-1990s, the mortality associated with multiple myeloma (MM) has decreased, with a substantial reduction observed with the introduction of proteasome inhibitors (Pis) and immunomodulatory drugs (IMiDs), according to the results of a retrospective study presented at the ESMO Congress 2022.
The treatment landscape for MM has evolved with the approval of Pis and IMiDs during the 2000s and additional agents, including monoclonal antibodies, approved since then and through the present. The aim of this study was to determine if the MM-specific mortality trends have changed as a result of new therapies.
The retrospective study evaluated data of patients with MM from the Surveillance, Epidemiology, and End Results (SEER) program from between 1975 to 2019.
Continue Reading
MM-specific mortality increased between 1975 and 1993 (annual percent change [APC] 1.49%; P <.01). However, there was a significant reduction in MM-specific mortality between 1993 and 2002 (APC, -0.49%; P <.01) and 2002 to 2009 (APC, -2.00; P <.01).
“With approval of more agents including monoclonal antibodies since 2012, routine use of frontline triplet therapy and maintenance therapy since mid-2011s, the significant trend in the decrease in mortality continued during 2012 to 2019,” the authors presented (APC, -1.61%; P <.01).
There was no change in mortality between 2009 and 2012 (APC, 1.29%; P =.38). The authors concluded that “changing treatment landscape seems to be correlating with changing epidemiology of MM.”
Disclosures: Some of the study authors declared affiliations with biotech, pharmaceutical, or device companies. Please see the original reference for a full list of disclosures.
Reference
Kahlon N, Abuhelwa Z, Sheikh T, et al. Multiple myeloma: Effect of changing treatment landscape on population mortality in United States. Presented at ESMO 2022; September 9-13, 2022. Abstract 637P.
